Von Willebrand's Disease - Pipeline Insight, 2025

This “Von Willebrand’s Disease - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Von Willebrand’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Von Willebrand’s Disease: Understanding

Von Willebrand’s Disease: Overview

Von Willebrand disease (VWD) is the most common inherited bleeding disorder, characterized by a deficiency or dysfunction of von Willebrand factor (VWF), a crucial protein for blood clotting. This condition impairs the ability of platelets to adhere to blood vessel walls, leading to abnormal bleeding tendencies. VWD is typically inherited in an autosomal dominant manner, with three main types: type 1, type 2, and type 3, each varying in severity and symptoms. Common manifestations include excessive bleeding from cuts, frequent nosebleeds, heavy menstrual bleeding, and prolonged bleeding after dental procedures or surgeries. Although there is no cure, treatment options such as desmopressin and clotting factor concentrates can help manage symptoms and enable individuals to lead active lives.

Symptoms of von Willebrand disease (VWD) can vary depending on the type and severity of the condition, but common signs include easy bruising, frequent nosebleeds that may last longer than 10 minutes, and heavy or prolonged menstrual bleeding. Individuals may experience excessive bleeding following cuts, injuries, surgeries, or dental procedures. Some may also notice blood in their urine or stool, and bleeding gums. In more severe cases, especially with type 3 VWD, spontaneous bleeding episodes can occur, and individuals may experience swelling and pain in joints and soft tissues due to internal bleeding. Many people with VWD may not exhibit noticeable symptoms unless they experience a bleeding event. The diagnosis of von Willebrand disease (VWD) involves a comprehensive evaluation that includes a detailed medical history and specific laboratory tests. Physicians typically begin by assessing the patient's bleeding history, including the frequency and severity of symptoms such as excessive bruising, prolonged bleeding from cuts, and heavy menstrual bleeding. Key laboratory tests include measuring the levels of von Willebrand factor (VWF) antigen, assessing VWF activity, and determining factor VIII clotting activity, as these can help identify the type and severity of VWD.

Treatment for von Willebrand disease (VWD) focuses on preventing or controlling bleeding episodes. Desmopressin (DDAVP) is often first-line for type 1 VWD, while VWF concentrates are used for severe cases like type 2 or type 3. Antifibrinolytic agents, such as tranexamic acid, help prevent clot breakdown, especially during surgery. Hormonal treatments, like oral contraceptives, are beneficial for women with heavy menstrual bleeding.

“Von Willebrand’s Disease - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Von Willebrand’s Disease pipeline landscape is provided which includes the disease overview and Von Willebrand’s Disease treatment guidelines. The assessment part of the report embraces, in depth Von Willebrand’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Von Willebrand’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Von Willebrand’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Von Willebrand’s Disease.

Von Willebrand’s Disease Emerging Drugs Chapters

This segment of the Von Willebrand’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Von Willebrand’s Disease Emerging Drugs

VGA039: Star Therapeutics

VGA039 is a monoclonal antibody therapy with a novel mechanism of action that targets Protein S, a key component in restoring balance to the blood clotting process. VGA039 has potential to be a universal hemostatic therapy that can treat numerous bleeding disorders, with the first disease indication of VWD. As a subcutaneously self-administered antibody therapy with a convenient dosing regimen, VGA039 has the potential to dramatically reduce treatment burden for patients. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Von Willebrand Disease.

Von Willebrand’s Disease: Therapeutic Assessment

This segment of the report provides insights about the different Von Willebrand’s Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Von Willebrand’s Disease

There are approx. 4+ key companies which are developing the therapies for Von Willebrand’s Disease. The companies which have their Von Willebrand’s Disease drug candidates in the most advanced stage, i.e. Phase I/II include Star Therapeutics.

Phases

The report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Von Willebrand’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Von Willebrand’s Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Von Willebrand’s Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Von Willebrand’s Disease drugs.

Von Willebrand’s Disease Report Insights

• Von Willebrand’s Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Von Willebrand’s Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Von Willebrand’s Disease drugs?
• How many Von Willebrand’s Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Von Willebrand’s Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Von Willebrand’s Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Von Willebrand’s Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Vega Therapeutics
• Hemab

Key Products

• VGA039
• HMB-002

This product will be delivered within 2 business days.